AMITIZA Drug Patent Profile

Which patents cover Amitiza, and when can generic versions of Amitiza launch?

Amitiza is a drug marketed by Sucampo Pharma Llc and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has twenty patent family members in fifteen countries.

The generic ingredient in AMITIZA is lubiprostone. There are ten drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the lubiprostone profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Amitiza

A generic version of AMITIZA was approved as lubiprostone by AMNEAL on November 30^th, 2021.

Summary for AMITIZA

International Patents:	20
US Patents:	3
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for AMITIZA

Paragraph IV (Patent) Challenges for AMITIZA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
AMITIZA	Capsules	lubiprostone	8 mcg and 24 mcg	021908	1	2012-08-20

US Patents and Regulatory Information for AMITIZA

AMITIZA is protected by three US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sucampo Pharma Llc	AMITIZA	lubiprostone	CAPSULE;ORAL	021908-002	Apr 29, 2008	AB	RX	Yes	No	8,779,187		Y
Sucampo Pharma Llc	AMITIZA	lubiprostone	CAPSULE;ORAL	021908-001	Jan 31, 2006	AB	RX	Yes	Yes	8,779,187		Y
Sucampo Pharma Llc	AMITIZA	lubiprostone	CAPSULE;ORAL	021908-002	Apr 29, 2008	AB	RX	Yes	No	8,026,393		Y
Sucampo Pharma Llc	AMITIZA	lubiprostone	CAPSULE;ORAL	021908-002	Apr 29, 2008	AB	RX	Yes	No	8,338,639		Y
Sucampo Pharma Llc	AMITIZA	lubiprostone	CAPSULE;ORAL	021908-001	Jan 31, 2006	AB	RX	Yes	Yes	8,338,639		Y
Sucampo Pharma Llc	AMITIZA	lubiprostone	CAPSULE;ORAL	021908-001	Jan 31, 2006	AB	RX	Yes	Yes	8,026,393		Y

International Patents for AMITIZA

See the table below for patents covering AMITIZA around the world.

Country	Patent Number	Title	Estimated Expiration
Denmark	1392318
Hungary	0302422
New Zealand	553434	Prostaglandin derivatives for treating gastrointestinal disorder
Taiwan	I302100
Austria	355067
Brazil	PI0707334
Australia	2007208632

Supplementary Protection Certificates for AMITIZA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1315485	49/2015	Austria		PRODUCT NAME: LUBIPROSTON UND PHARMAZEUTISCH ANNEHMBARE SALZE DAVON; NAT. REGISTRATION NO/DATE: 136176 20150508; FIRST REGISTRATION: GB PL 21341/0003 20120910
1315485	2015C/048	Belgium		PRODUCT NAME: LUBIPROSTONE; AUTHORISATION NUMBER AND DATE: PL21341/0003 20150317
2298314	92826	Luxembourg		PRODUCT NAME: LUBIPROSTONE, INCLUANT LES SELS PHARMACEUTIQUEMENT ACCEPTABLES, LES ESTERS OU LES AMIDES DE LA LUBIPROSTONE. FIRST REGISTRATION: 20120910
1315485	2015/028	Ireland		PRODUCT NAME: LUBIPROSTONE AND PHARMACEUTICALLY ACCEPTABLE SALTS FOR LUBIPROSTONE.; NAT REGISTRATION NO/DATE: PA148/002/001 20150213; FIRST REGISTRATION NO/DATE: PL21341/0003-0001 20120910
1315485	C01315485/01	Switzerland		FORMER REPRESENTATIVE: BOHEST AG, CH
1315485	300757	Netherlands		PRODUCT NAME: LUBIPROSTON; NATIONAL REGISTRATION NO/DATE: RVG 115891; FIRST REGISTRATION NO/DATE: PL21341/0003 20120910
1315485	122015000080	Germany		PRODUCT NAME: LUBIPROSTON, ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; NAT. REGISTRATION NO/DATE: 92699.00.00 20150519; FIRST REGISTRATION: VEREINIGTES KOENIGREICH PL 21341/0003 20120910

AMITIZA (Lubiprostone) Investment Analysis

Last updated: February 19, 2026

AMITIZA (lubiprostone), a bicyclic fatty acid derivative, is a prescription medication indicated for the treatment of chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C) in adult women. Developed by Sucampo Pharmaceuticals and later marketed by Takeda Pharmaceutical Company, AMITIZA's efficacy stems from its activation of chloride channels in the intestinal epithelium, increasing fluid secretion and facilitating stool passage. This analysis examines AMITIZA's market position, patent landscape, competitive environment, and financial performance to inform investment decisions.

What is the Current Market Position of AMITIZA?

AMITIZA holds a established position in the niche market for chronic constipation and IBS-C treatments. Its mechanism of action, which increases intestinal fluid secretion, differentiates it from bulk-forming laxatives and osmotic agents. The drug's approval for both CIC and IBS-C broadens its patient population.

• Target Indications:

  • Chronic Idiopathic Constipation (CIC)
  • Irritable Bowel Syndrome with Constipation (IBS-C) in adult women

• Market Penetration: AMITIZA has achieved significant market penetration since its initial FDA approval in 2006. Its sustained prescription volume indicates consistent demand from patients and healthcare providers seeking effective treatment options for these conditions.

• Patient Demographics: The primary patient demographic is adult women experiencing chronic constipation or IBS-C. This demographic often faces long-term management needs, supporting sustained revenue streams.

• Therapeutic Landscape: The therapeutic landscape for constipation is diverse, including over-the-counter (OTC) options, prescription medications, and lifestyle interventions. AMITIZA competes within the prescription segment, where it is positioned as a reliable and effective therapy.

What is the Patent Status and Exclusivity Landscape for AMITIZA?

The patent portfolio surrounding AMITIZA is critical to understanding its market exclusivity and the potential for generic competition. Key patents protect the composition of matter, methods of use, and manufacturing processes.

• Original Patent Expiration: The primary composition of matter patents for lubiprostone expired. For example, U.S. Patent 5,272,146, related to the preparation and use of certain types of prostaglandin derivatives, expired in 2012 [1].

• Evergreening Strategies: Pharmaceutical companies often employ strategies to extend market exclusivity. These can include:

  • Method-of-Use Patents: Patents covering specific uses of the drug, such as treating IBS-C, can extend exclusivity for that particular indication. For instance, patents related to the use of lubiprostone for IBS-C were pursued after the initial CIC indication.
  • Formulation Patents: Development of new formulations or delivery systems can lead to additional patent protection.
  • Manufacturing Process Patents: Improvements in manufacturing processes can also be patented.

• Generic Entry: With the expiration of core patents, generic versions of lubiprostone have entered the market. This typically leads to a significant decline in the brand-name drug's market share and pricing power. The timing and impact of generic entry are crucial for investment analysis.

• Orange Book Listings: The U.S. Food and Drug Administration's (FDA) Orange Book lists patents and exclusivities for approved drugs. Analyzing these listings provides a definitive record of patent protection and expiration dates for AMITIZA and its generic equivalents.

• Post-Patent Exclusivity: While patent exclusivity is paramount, other forms of market protection exist, such as:

  • Data Exclusivity: Following new drug approvals (e.g., for a new indication), a period of data exclusivity may be granted, preventing generics from relying on the innovator's clinical trial data.

What is the Competitive Landscape for AMITIZA?

AMITIZA operates in a competitive market for gastrointestinal motility disorders. Competitors can be categorized by their mechanism of action and indication.

• Direct Competitors (Prescription, IBS-C/CIC):

  • LINZESS (linaclotide): A guanylate cyclase-C (GC-C) agonist that increases intestinal fluid secretion and transit. It is approved for both CIC and IBS-C. LINZESS has become a dominant player in this space since its approval in 2012.
  • TRULANCE (plecanatide): Another GC-C agonist, similar in mechanism to linaclotide, approved for CIC and IBS-C. It entered the market after LINZESS.

• Other Prescription Agents (Broader Mechanisms):

  • AMITIZA (lubiprostone): Chloride channel activator.
  • Movantik (naloxegol): A peripherally acting mu-opioid receptor antagonist used for opioid-induced constipation.
  • Relistor (methylnaltrexone bromide): Another peripherally acting mu-opioid receptor antagonist for opioid-induced constipation.
  • Lubiprostone Generics: As core patents expired, multiple generic manufacturers have introduced lubiprostone products, directly competing with brand-name AMITIZA.

• Over-the-Counter (OTC) Options:

  • Bulk-forming agents: Psyllium (e.g., Metamucil), methylcellulose (e.g., Citrucel).
  • Osmotic laxatives: Polyethylene glycol (e.g., MiraLAX), magnesium hydroxide (e.g., Milk of Magnesia).
  • Stimulant laxatives: Bisacodyl (e.g., Dulcolax), senna (e.g., Senokot).

• Market Share Dynamics: The introduction of GC-C agonists like LINZESS and TRULANCE has significantly impacted AMITIZA's market share. Generic lubiprostone has further eroded the brand's revenue. The choice of therapy often depends on physician preference, patient response, and cost.

What are the Financial Performance and Market Valuation Drivers of AMITIZA?

The financial performance of AMITIZA is directly tied to its sales, prescription trends, and the impact of generic competition and its associated pricing pressures.

• Historical Sales Performance (Brand AMITIZA):

  • Pre-generic entry, AMITIZA generated substantial revenue for Sucampo Pharmaceuticals and later Takeda. For example, in its peak years, brand AMITIZA sales exceeded several hundred million dollars annually.
  • Takeda acquired Sucampo Pharmaceuticals in 2017, integrating AMITIZA into its gastroenterology portfolio.

• Impact of Generic Entry:

  • Upon the introduction of generic lubiprostone, brand AMITIZA sales have experienced a significant and predictable decline. This is a standard trend in the pharmaceutical industry.
  • Pricing for generic lubiprostone is substantially lower than the brand-name product, leading to reduced overall market value for the molecule.

• Revenue Streams:

  • Brand Sales: Declining but still contributing to Takeda's portfolio.
  • Licensing/Royalty Agreements: Sucampo and Takeda may have had existing agreements that continue to generate revenue.

• Market Valuation Factors:

  • Patent Expiry: The primary driver of valuation decline for branded pharmaceuticals.
  • Generic Competition: The speed and intensity of generic entry directly impact revenue.
  • Market Size of Indications: The prevalence and treatment rates of CIC and IBS-C are key.
  • Pipeline and Portfolio: For Takeda, AMITIZA is one product within a broader GI portfolio. Its contribution to the overall company valuation is relative to other assets.
  • R&D Investment: The ongoing investment in lubiprostone's lifecycle management (if any) or in competing therapies by the owner.

• Takeda's Strategic Position: For Takeda, AMITIZA represents a mature product. The company’s focus would likely be on optimizing its sales, managing the transition to generics, and leveraging its GI expertise in other areas of its pipeline.

What are the Key Challenges and Future Outlook for AMITIZA?

AMITIZA faces significant challenges primarily stemming from patent expirations and the ensuing generic competition, alongside evolving treatment paradigms.

• Generic Erosion: The most significant challenge is the continued erosion of market share and pricing power due to the availability of lower-cost generic lubiprostone. This trend is irreversible for the branded product.

• Competition from Newer Agents: Newer therapies like linaclotide (LINZESS) and plecanatide (TRULANCE) with different mechanisms of action have gained traction and are often preferred in treatment guidelines due to perceived efficacy or convenience.

• Evolving Treatment Guidelines: Medical guidelines for managing constipation and IBS-C are dynamic. Shifts in recommendations can favor newer or different classes of drugs, impacting AMITIZA's prescribing volume.

• Limited Differentiation: As generic versions become widely available, the differentiation between branded AMITIZA and its generic counterparts diminishes, further commoditizing the molecule.

• Future Outlook:

  • Brand AMITIZA: The future for branded AMITIZA is characterized by a continuous decline in sales. Its primary role will be serving patients who specifically request or respond best to the branded formulation, or in markets where generic availability is delayed.
  • Lubiprostone Molecule: The lubiprostone molecule will continue to be prescribed through its generic versions. Investment focus would shift from the brand to the generic manufacturers who can produce and distribute it cost-effectively.
  • Takeda's Portfolio Management: Takeda will likely continue to manage AMITIZA as a mature product, focusing on profitability from its remaining brand sales and potentially exploring opportunities in combination therapies or new markets, though significant growth is not anticipated.

Key Takeaways

AMITIZA (lubiprostone) has transitioned from a growth-stage branded pharmaceutical to a mature product facing substantial generic competition. Its patent exclusivity has expired, leading to the market entry of multiple generic lubiprostone versions. This has resulted in a significant decline in brand-name AMITIZA sales and market share, a predictable outcome for a drug post-patent expiration. Newer direct competitors like LINZESS and TRULANCE have also captured significant market share in the IBS-C and CIC indications. The future outlook for branded AMITIZA is one of continued sales decline, with the molecule's ongoing utility primarily residing in its generic formulations. Investment considerations should focus on the economics of generic manufacturing and distribution rather than the branded product.

FAQs

1. When did the main patents for AMITIZA expire, allowing for generic competition? The core composition of matter patents for lubiprostone expired around 2012, with subsequent patents related to specific methods of use also expiring over time, paving the way for generic entry.

2. What is the primary mechanism of action for AMITIZA? AMITIZA is a chloride channel activator. It increases fluid secretion in the intestinal lumen by activating type-2 chloride channels (ClC-2) on the apical membrane of the intestinal epithelium, which facilitates stool passage.

3. What are the main therapeutic indications for AMITIZA? AMITIZA is indicated for the treatment of chronic idiopathic constipation (CIC) in adult women and irritable bowel syndrome with constipation (IBS-C) in adult women.

4. How has the introduction of generic lubiprostone affected the sales of branded AMITIZA? The introduction of generic lubiprostone has led to a substantial decrease in the sales revenue and market share of branded AMITIZA, a common phenomenon in the pharmaceutical industry following patent expiration.

5. Are there other prescription medications that compete directly with AMITIZA for IBS-C and CIC? Yes, key competitors include LINZESS (linaclotide) and TRULANCE (plecanatide), which are guanylate cyclase-C (GC-C) agonists and have captured significant market share in these indications.

Citations

[1] U.S. Patent 5,272,146. (1993). Process for preparing prostaglandin derivatives. Retrieved from USPTO.